In a cohort of patients reclassified according to the 2021 WHO, preoperative tumor size was an independent predictor of survival in both the IDH-mutant astrocytoma and IDH-mutant 1p19q codeleted oligodendroglioma subgroups (42). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).